These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31294444)

  • 1. Established PABPN1 intranuclear inclusions in OPMD muscle can be efficiently reversed by AAV-mediated knockdown and replacement of mutant expanded PABPN1.
    Malerba A; Klein P; Lu-Nguyen N; Cappellari O; Strings-Ufombah V; Harbaran S; Roelvink P; Suhy D; Trollet C; Dickson G
    Hum Mol Genet; 2019 Oct; 28(19):3301-3308. PubMed ID: 31294444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PABPN1 gene therapy for oculopharyngeal muscular dystrophy.
    Malerba A; Klein P; Bachtarzi H; Jarmin SA; Cordova G; Ferry A; Strings V; Espinoza MP; Mamchaoui K; Blumen SC; St Guily JL; Mouly V; Graham M; Butler-Browne G; Suhy DA; Trollet C; Dickson G
    Nat Commun; 2017 Mar; 8():14848. PubMed ID: 28361972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy.
    Roth F; Dhiab J; Boulinguiez A; Mouigni HR; Lassche S; Negroni E; Muraine L; Marhic A; Oliver A; Lainé J; Rouche A; O'Ferrall EK; van Engelen B; Ottenheijm C; Greif H; Blumen S; Lacau St Guily J; Perie S; Butler-Browne G; Mouly V; Trollet C
    Acta Neuropathol; 2022 Dec; 144(6):1157-1170. PubMed ID: 36197469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy.
    Doki T; Yamashita S; Wei FY; Hara K; Yamamoto T; Zhang Z; Zhang X; Tawara N; Hino H; Uyama E; Kurashige T; Maruyama H; Tomizawa K; Ando Y
    Lab Invest; 2019 Nov; 99(11):1728-1740. PubMed ID: 30894671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres.
    Trollet C; Anvar SY; Venema A; Hargreaves IP; Foster K; Vignaud A; Ferry A; Negroni E; Hourde C; Baraibar MA; 't Hoen PA; Davies JE; Rubinsztein DC; Heales SJ; Mouly V; van der Maarel SM; Butler-Browne G; Raz V; Dickson G
    Hum Mol Genet; 2010 Jun; 19(11):2191-207. PubMed ID: 20207626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranuclear Aggregates Precede Clinical Onset in Oculopharyngeal Muscular Dystrophy.
    van der Sluijs BM; Raz V; Lammens M; van den Heuvel LP; Voermans NC; van Engelen BG
    J Neuromuscul Dis; 2016 Mar; 3(1):101-109. PubMed ID: 27854203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.
    Abu-Baker A; Laganiere S; Fan X; Laganiere J; Brais B; Rouleau GA
    Traffic; 2005 Sep; 6(9):766-79. PubMed ID: 16101680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy.
    Harish P; Malerba A; Dickson G; Bachtarzi H
    Hum Gene Ther; 2015 May; 26(5):286-92. PubMed ID: 25860803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy.
    Hino H; Araki K; Uyama E; Takeya M; Araki M; Yoshinobu K; Miike K; Kawazoe Y; Maeda Y; Uchino M; Yamamura K
    Hum Mol Genet; 2004 Jan; 13(2):181-90. PubMed ID: 14645203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.
    Vest KE; Phillips BL; Banerjee A; Apponi LH; Dammer EB; Xu W; Zheng D; Yu J; Tian B; Pavlath GK; Corbett AH
    Hum Mol Genet; 2017 Sep; 26(17):3235-3252. PubMed ID: 28575395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic analysis reveals that wildtype and alanine-expanded nuclear poly(A)-binding protein exhibit differential interactions in skeletal muscle.
    Banerjee A; Phillips BL; Deng Q; Seyfried NT; Pavlath GK; Vest KE; Corbett AH
    J Biol Chem; 2019 May; 294(18):7360-7376. PubMed ID: 30837270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients.
    Gidaro T; Negroni E; Perié S; Mirabella M; Lainé J; Lacau St Guily J; Butler-Browne G; Mouly V; Trollet C
    J Neuropathol Exp Neurol; 2013 Mar; 72(3):234-43. PubMed ID: 23399899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal model of oculopharyngeal muscular dystrophy.
    Uyama E; Hino H; Araki K; Takeya M; Uchino M; Yamamura K
    Acta Myol; 2005 Oct; 24(2):84-8. PubMed ID: 16550922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.
    Corbeil-Girard LP; Klein AF; Sasseville AM; Lavoie H; Dicaire MJ; Saint-Denis A; Pagé M; Duranceau A; Codère F; Bouchard JP; Karpati G; Rouleau GA; Massie B; Langelier Y; Brais B
    Neurobiol Dis; 2005 Apr; 18(3):551-67. PubMed ID: 15755682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging.
    Anvar SY; Raz Y; Verway N; van der Sluijs B; Venema A; Goeman JJ; Vissing J; van der Maarel SM; 't Hoen PA; van Engelen BG; Raz V
    Aging (Albany NY); 2013 Jun; 5(6):412-26. PubMed ID: 23793615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies.
    Abu-Baker A; Rouleau GA
    Biochim Biophys Acta; 2007 Feb; 1772(2):173-85. PubMed ID: 17110089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear entrapment and extracellular depletion of PCOLCE is associated with muscle degeneration in oculopharyngeal muscular dystrophy.
    Raz V; Sterrenburg E; Routledge S; Venema A; van der Sluijs BM; Trollet C; Dickson G; van Engelen BG; van der Maarel SM; Antoniou MN
    BMC Neurol; 2013 Jul; 13():70. PubMed ID: 23815790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells.
    Wang Q; Mosser DD; Bag J
    Hum Mol Genet; 2005 Dec; 14(23):3673-84. PubMed ID: 16239242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Japanese case of oculopharyngeal muscular dystrophy (OPMD) with PABPN1 c.35G > C; p.Gly12Ala point mutation.
    Nishii YS; Noto YI; Yasuda R; Kitaoji T; Ashida S; Tanaka E; Minami N; Nishino I; Mizuno T
    BMC Neurol; 2021 Jul; 21(1):265. PubMed ID: 34225694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy.
    Fan X; Messaed C; Dion P; Laganiere J; Brais B; Karpati G; Rouleau GA
    Can J Neurol Sci; 2003 Aug; 30(3):244-51. PubMed ID: 12945950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.